Back to Search
Start Over
MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy
- Source :
- Blood; November 2022, Vol. 140 Issue: Supplement 1 p4418-4419, 2p
- Publication Year :
- 2022
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 140
- Issue :
- Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs61223975
- Full Text :
- https://doi.org/10.1182/blood-2022-162733